VRC is proud to release its latest Industry Report. The report provides a concise, insightful update on the Biotechnology industry including recent transactions, market multiples, company performance and purchase price allocation percentages.
Read the full report: Biotechnology: October 2020
October 2020 Industry Highlights
- After historic drops in deal activity, approximately 45% year-to-date, US M&A deal activity responded in the third quarter with over $400 billion in deal value, an increase of more than 4x quarter-over-quarter, and over 1,000 total transactions, an increase of approximately 22% quarter-over-quarter. There were nearly 3,500 total deals globally, around 32% decrease compared to the third quarter of 2019. YTD, total deal volumes are nearly 27% lower compared to the same period in 2019 but have strongly rebounded in the third quarter with tepid optimism for the remainder of 2020, given the US election and uncertainties related to COVID.
- On August 31, 2020, Ionis Pharmaceuticals, Inc. and its affiliate Akcea Therapeutics, Inc. announced that they have entered into a definitive agreement under which Ionis will acquire all of the outstanding shares of Akcea common stock it does not already own, approximately 24%, for $18.15 per share in cash. This corresponds to a total transaction value of approximately $500 million on a fully diluted basis.
Past Industry Updates: